5'-amino-3',5'-dideoxyadenosine | 125944-06-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 5'-amino-3',5'-dideoxyadenosine
• 英文别名: (2R,3R,5S)-5-(aminomethyl)-2-(6-aminopurin-9-yl)tetrahydrofuran-3-ol；(2R,3R,5S)-5-(aminomethyl)-2-(6-aminopurin-9-yl)oxolan-3-ol
• CAS: 125944-06-1
• 化学式: C₁₀H₁₄N₆O₂
• 分子量: 250.26
• InChiKey: OUWWPEOHTKKJPJ-BAJZRUMYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  125
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5'-amino-3',5'-dideoxyadenosine 在 四氮唑 、 氯化铵 、 六甲基二硅氮烷 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 18.5h， 生成 3',5'-dideoxy-N⁶-<2-(4-nitrophenyl)ethoxycarbonyl>-5'-<<2-(4-nitrophenyl)ethoxycarbonyl>amino>adenosine 2'-O-<2-cyanoethyl diisopropylphosphoramidite>
  参考文献：
  名称：

  Nucleotides

  摘要：

  DOI：

  10.1002/(sici)1522-2675(19990113)82:1<19::aid-hlca19>3.0.co;2-g
• 作为产物：
  描述：

  N-苯甲酰基-3'-脱氧腺苷 在 吡啶 、 ammonium hydroxide 、 叠氮化锂 、 三苯基膦 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 25.0h， 生成 5'-amino-3',5'-dideoxyadenosine
  参考文献：
  名称：

  Nucleotides

  摘要：

  DOI：

  10.1002/(sici)1522-2675(19990113)82:1<19::aid-hlca19>3.0.co;2-g

文献信息

• Non-stochastic generation of genetic vaccines and enzymes
  申请人：BP Corporation North America Inc.

  公开号：EP2397549A2

  公开（公告）日：2011-12-21

  This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by use of non-stochastic methods of directed evolution (DirectEvolution™). These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis™) and non-stochastic polynucleotide reassembly (GeneReassembly™). Through use of the claimed methods, genetic vaccines, enzymes, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors can be obtained that exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like. This invention provides methods of obtaining novel enzymes that have optimized physical and/or biological properties. Furthermore, this invention provides methods of obtaining a variety of novel biologically active molecules, in the fields of antibiotics, pharmacotherapeutics, and transgenic traits.

  本发明提供了通过使用非随机定向进化方法（DirectEvolution™）获得新型多核苷酸和编码多肽的方法。这些方法包括非随机多核苷酸位点饱和诱变（Gene Site Saturation Mutagenesis™）和非随机多核苷酸重组（GeneReassembly™）。通过使用上述方法，基因疫苗、酶和其他理想的分子可以向理想的特性进化。例如，获得的疫苗载体可以提高作为基因疫苗的效力。例如，通过使用这些方法获得的载体可具有增强的抗原表达能力、增强的细胞吸收能力、增强的细胞稳定性、定制免疫反应的能力等。本发明提供了获得具有优化物理和/或生物特性的新型酶的方法。此外，本发明还提供了在抗生素、药物治疗和转基因性状领域获得各种新型生物活性分子的方法。
• Synthetic ligation reassembly in directed evolution
  申请人：BP Corporation North America Inc.

  公开号：EP2865754A1

  公开（公告）日：2015-04-29

  The invention is directed to a process of preparing nucleic acid and poly nucleotide libraries by cloning non-randomly generated nucleotide fragments having ligatable ends into an expression vector. The expression of the polynucleotide provides an indirect means by which to screen the polynucleotide library.

  本发明涉及一种通过将具有可连接末端的非随机产生的核苷酸片段克隆到表达载体中来制备核酸和多核苷酸文库的方法。多核苷酸的表达为筛选多核苷酸文库提供了一种间接方法。
• End selection in directed evolution
  申请人：——

  公开号：US20020146762A1

  公开（公告）日：2002-10-10

  This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by the use of non-stochastic methods of directed evolution (DirectEvolution™). A particular advantage of end-selection-based methods is the ability to recover full-length polynucleotides from a library of progeny molecules generated by mutagenesis methods. These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis™) and non-stochastic polynucleotide reassembly (GeneReassembly™). This invention provides methods of obtaining novel enzymes that have optimized physical &/or biological properties. Through use of the claimed methods, genetic vaccines, enzymes, small molecules, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors, can be obtained that exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like. Furthermore, this invention provides methods of obtaining a variety of novel biologically active molecules, in the fields of antibiotics, pharmacotherapeutics, and transgenic traits.

  本发明提供了通过使用非随机定向进化方法（DirectEvolution™）获得新型多核苷酸和编码多肽的方法。基于末端选择的方法的一个特别优势是从诱变方法产生的后代分子库中恢复全长多核苷酸的能力。这些方法包括非随机多核苷酸位点饱和诱变（Gene Site Saturation Mutagenesis™）和非随机多核苷酸重组（GeneReassembly™）。本发明提供了获得具有优化物理和/或生物特性的新型酶的方法。通过使用所要求的方法，基因疫苗、酶、小分子和其他理想分子可以向理想特性进化。例如，获得的疫苗载体可以提高作为基因疫苗使用的效力。例如，使用本发明方法获得的载体可具有增强的抗原表达能力、增强的细胞吸收能力、增强的细胞稳定性、定制免疫反应的能力等。此外，本发明还提供了在抗生素、药物治疗和转基因性状领域获得各种新型生物活性分子的方法。
• Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
  申请人：Diversa Corporation

  公开号：US20030219752A1

  公开（公告）日：2003-11-27

  The invention is directed to methods for generating sets, or libraries, of nucleic acids encoding antigen-binding sites, such as antibodies, antibody domains or other fragments, including single and double stranded antibodies, major histocompatibility complex (MHC) molecules, T cell receptors (TCRs), and the like. This invention provides methods for generating variant antigen binding sites, e.g., antibodies and specific domains or fragments of antibodies (e.g., Fab or Fc domains), by altering template nucleic acids including by saturation mutagenesis, synthetic ligation reassembly, or a combination thereof. In one aspect, invention provides methods for generating all human or humanized antibodies and evolving them to achieve optimized properties related to stability, duration, expression, production, enzymatic activity, affinity, avidity, localization, and other immunological properties. Polypeptides generated by these methods can be analyzed using a novel capillary array platform, which provides unprecedented ultra-high throughput screening.

  本发明涉及生成编码抗原结合位点（如抗体、抗体结构域或其他片段，包括单链和双链抗体、主要组织相容性复合体（MHC）分子、T细胞受体（TCR）等）的核酸集或核酸库的方法。本发明提供了通过改变模板核酸（包括饱和诱变、合成连接重组或它们的组合）来产生变体抗原结合位点的方法，例如抗体和抗体的特定结构域或片段（如 Fab 或 Fc 结构域）。在一个方面，本发明提供了生成全人源或人源化抗体的方法，并使其进化以获得与稳定性、持续时间、表达、生产、酶活性、亲和力、亲和性、定位和其他免疫学特性相关的优化特性。通过这些方法生成的多肽可使用新型毛细管阵列平台进行分析，该平台可提供前所未有的超高通量筛选。
• Non-stochastic generation of genetic vaccines
  申请人：——

  公开号：US20030207287A1

  公开（公告）日：2003-11-06

  This invention provides methods of obtaining vaccines by use of non-stochastic methods of directed evolution (DirectEvolution™). These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis™) and non-stochastic polynucleotide reassembly (GeneReassembly™). Through use of the claimed methods, vectors can be obtained which exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like.

  本发明提供了通过使用非随机定向进化方法（DirectEvolution™）获得疫苗的方法。这些方法包括非随机多核苷酸位点饱和诱变（Gene Site Saturation Mutagenesis™）和非随机多核苷酸重组（GeneReassembly™）。通过使用上述方法，可以获得更有效的基因疫苗载体。例如，通过使用这些方法获得的载体可以增强抗原表达、增加细胞吸收、增加细胞稳定性、定制免疫反应的能力等。